Proteomics

Dataset Information

0

SHMT2 controls Burkitt lymphoma cell survival by maintaining an oncogenic TCF3 transcriptional program

ABSTRACT: In this study, the human Burkitt’s Lymphoma cell line BL60 has been analysed via proteomic and phosphoproteomic analysis for effect of a knock down of the serine hydroxymethyltransferase 2 (shSHMT2) compared to a control construct (shGL2). Concerning the phosphoproteome, these results have been compared to an analysis of a knock down of CD79a (shCD79a) in these cells.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Burkitt Lymphoma Cell Line

DISEASE(S): Burkitt Lymphoma

SUBMITTER: Anne Wilke  

LAB HEAD: Thomas Oellerich

PROVIDER: PXD018961 | Pride | 2023-03-10

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.

Wilke Anne C AC   Doebele Carmen C   Zindel Alena A   Lee Kwang Seok KS   Rieke Sara A SA   Ceribelli Michele M   Comoglio Federico F   Phelan James D JD   Wang James Q JQ   Pikman Yana Y   Jahn Dominique D   Häupl Björn B   Schneider Constanze C   Scheich Sebastian S   Tosto Frances A FA   Bohnenberger Hanibal H   Stauder Philipp P   Schnütgen Frank F   Slabicki Mikolaj M   Coulibaly Zana A ZA   Wolf Sebastian S   Bojarczuk Kamil K   Chapuy Björn B   Brandts Christian H CH   Stroebel Philipp P   Lewis Caroline A CA   Engelke Michael M   Xu Xincheng X   Kim Hahn H   Dang Thanh Hung TH   Schmitz Roland R   Hodson Daniel J DJ   Stegmaier Kimberly K   Urlaub Henning H   Serve Hubert H   Schmitt Clemens A CA   Kreuz Fernando F   Knittel Gero G   Rabinowitz Joshua D JD   Reinhardt Hans Christian HC   Vander Heiden Matthew G MG   Thomas Craig C   Staudt Louis M LM   Zenz Thorsten T   Oellerich Thomas T  

Blood 20220101 4

Burkitt lymphoma (BL) is an aggressive lymphoma type that is currently treated by intensive chemoimmunotherapy. Despite the favorable clinical outcome for most patients with BL, chemotherapy-related toxicity and disease relapse remain major clinical challenges, emphasizing the need for innovative therapies. Using genome-scale CRISPR-Cas9 screens, we identified B-cell receptor (BCR) signaling, specific transcriptional regulators, and one-carbon metabolism as vulnerabilities in BL. We focused on s  ...[more]

Similar Datasets

Proteomics Time resolved quantitative phospho-tyrosine analysis reveals Bruton’s Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors
2018-07-11 | PXD009662 | Pride
Transcriptomics Streptococcus pneumoniae D39 wild-type grown in CDM+10 mM arginine compared to D39 wild type grown in CDM + 0.05 mM arginine
2011-11-02 | E-GEOD-33036 | biostudies-arrayexpress
Transcriptomics Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane treated human breast epithelial cells
2011-04-22 | E-GEOD-28813 | biostudies-arrayexpress
Proteomics Trypanosoma brucei whole cell proteome changes upon exposure to the aminomethyl-benzoxaborole AN3057
2024-03-25 | PXD049328 | Pride
Proteomics Uncovering structural themes across cilia microtubule inner proteins with implications for human cilia function
2024-03-01 | PXD037582 | Pride
Proteomics Characterization of RAS and SLC3A2 signaling in multiple myeloma
2022-10-14 | PXD031662 | Pride
Proteomics,Multiomics A systems study reveals concurrent activation of AMPK and mTOR by amino acids
2016-12-12 | PXD003073 | Pride
Proteomics Dynamic profiling of the protein life cycle in response to pathogens (protein)
2015-03-06 | E-GEOD-59792 | biostudies-arrayexpress
Proteomics Characterisation of cullin E3 ubiquitin ligases in trypanosomes
2024-03-25 | PXD042022 | Pride
Proteomics Targeting N-linked Glycosylation for the Therapy of Human Lymphoma
2023-04-22 | PXD036363 | Pride